Deucravacitinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 346 publications

Evaluation of the clinical applicability of artificial intelligence in determining systemic therapy indications and treatment selection in psoriasis.

Evaluation of the clinical applicability of artificial intelligence in determining systemic therapy indications and treatment selection in psoriasis.

Journal: The Journal of dermatological treatment

Published: June 20, 2026

Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination Therapy.

Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination Therapy.

Journal: Journal of cutaneous medicine and surgery

Published: June 05, 2026

Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.

Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.

Journal: Skin therapy letter

Published: May 27, 2026

Quality-of-life impact rather than overall severity may help guide therapeutic options in psoriasis.

Quality-of-life impact rather than overall severity may help guide therapeutic options in psoriasis.

Journal: Journal of the American Academy of Dermatology

Published: April 27, 2026

Editor's Highlights-June 2026.

Editor's Highlights-June 2026.

Journal: International journal of dermatology

Published: April 21, 2026

TYK2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded.

TYK2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded.

Journal: The British journal of dermatology

Published: April 20, 2026

Clearance of Cutaneous Lichen Planus with Deucravacitinib.

Clearance of Cutaneous Lichen Planus with Deucravacitinib.

Journal: The Journal of clinical and aesthetic dermatology

Published: March 27, 2026

TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris.

TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris.

Journal: medRxiv : the preprint server for health sciences

Published: March 27, 2026

Deucravacitinib in Moderate-to-Severe Plaque Psoriasis: A Real-World Study of Effectiveness and Safety in Clinical Practice.

Deucravacitinib in Moderate-to-Severe Plaque Psoriasis: A Real-World Study of Effectiveness and Safety in Clinical Practice.

Journal: Clinical and experimental dermatology

Published: March 27, 2026

Advances in the use of Janus kinase inhibitors.

Advances in the use of Janus kinase inhibitors.

Journal: Current opinion in rheumatology

Published: March 17, 2026

Discovery of potential covalent TYK2 inhibitors targeting Cys736 for the treatment of psoriasis.

Discovery of potential covalent TYK2 inhibitors targeting Cys736 for the treatment of psoriasis.

Journal: Bioorganic & medicinal chemistry

Published: March 09, 2026

Bullous Pemphigoid Possibly Induced by Deucravacitinib in a Patient with Psoriasis.

Bullous Pemphigoid Possibly Induced by Deucravacitinib in a Patient with Psoriasis.

Journal: Clinical, cosmetic and investigational dermatology

Published: March 06, 2026

Showing 1-12 of 346

Last Updated: 06/30/2026